FDA rejects Coherus' reworked Neulasta biosimilar due to third-party inspections
The FDA has rejected Coherus BioSciences’ new presentation for its Udenyca (pegfilgrastim-cbqv) biosimilar due to an inspection at one of its contractors.
Coherus said the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.